The Economic Times

Biocon forecasts stronger second half of FY27 with multiple growth drivers despite Q2 profit decline

Biocon anticipates a robust second half of FY27, supported by several key product launches and increasing insulin sales. The company noted a 52% decline in consolidated net profit, attributed to delayed shipments affecting quarterly revenue. Ustekinumab and Aflibercept biosimilars are projected to boost sales in the US market significantly. Additionally, the launch of Pertuzumab in Europe and Brazil is expected to generate substantial revenue.